Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Assets: 2021-2025

Historic Return on Assets for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to -0.40%.

  • SAB Biotherapeutics' Return on Assets rose 39.00% to -0.40% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.40%, marking a year-over-year increase of 39.00%. This contributed to the annual value of -0.65% for FY2024, which is 3.00% down from last year.
  • According to the latest figures from Q3 2025, SAB Biotherapeutics' Return on Assets is -0.40%, which was up 66.70% from -1.20% recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Return on Assets peaked at -0.17% during Q4 2021, and registered a low of -1.20% during Q2 2025.
  • Its 3-year average for Return on Assets is -0.73%, with a median of -0.75% in 2023.
  • The largest annual percentage gain for SAB Biotherapeutics' Return on Assets in the last 5 years was 39bps (2025), contrasted with its biggest fall of 59bps (2025).
  • Over the past 5 years, SAB Biotherapeutics' Return on Assets (Quarterly) stood at -0.17% in 2021, then declined by 19bps to -0.36% in 2022, then plummeted by 39bps to -0.75% in 2023, then grew by 9bps to -0.67% in 2024, then spiked by 39bps to -0.40% in 2025.
  • Its Return on Assets was -0.40% in Q3 2025, compared to -1.20% in Q2 2025 and -0.93% in Q1 2025.